From Medscape Gastroenterology

Conference Coverage from

The Liver Meeting 2017: American Association for the Study of Liver Diseases (AASLD)

October 20 - 24, 2017; Washington DC

October 20 - 24, 2017 Washington DC

AASLD Fatty Liver Common After Direct-Acting Antivirals for Hep C After hepatitis C is cured, patients should be monitored for steatosis and progression to fibrosis, new research indicates.
Medscape Medical News, October 30, 2017

Conference News

AASLD Fatty Liver Common After Direct-Acting Antivirals for Hep C
Medscape Medical News, October 30, 2017
AASLD Diabetes Medications Have Different Effects on the Liver
Medscape Medical News, October 26, 2017
AASLD New Drug Trims Liver Fat, But Triglyceride Levels Perplex
Medscape Medical News, October 25, 2017

AASLD Primary Care Screening for Fatty Liver Disease Debated
Medscape Medical News, October 23, 2017
AASLD NAFLD Increases Risk for Cardiovascular Events in Women
Medscape Medical News, October 22, 2017
AASLD Progress in Fatty Liver and Pediatric Liver Disease
Medscape Medical News, October 11, 2017

Popular News From AASLD 2016

Direct-Acting Antivirals for Hep C Might Worsen Liver Cancer For patients with hepatitis C and cirrhosis who develop hepatocellular carcinoma during treatment or follow-up, there is a trend toward disease worsening, new research shows.
Medscape Medical News, Nov 13, 2016
Novel Treatment Could Lead to Functional Control of Hep B Nucleic acid polymers block the release of the hepatitis B surface antigen from hepatocytes, boosting the efficacy of standard antiviral therapy, according to an early clinical trial.
Medscape Medical News, Nov 17, 2016
Mortality Risk Halved With Statin Use in Alcoholic Cirrhosis Statins reduced mortality risk for patients with compensated and decompensated alcoholic cirrhosis in a retrospective study, and also reduced the risk for decompensation.
Medscape Medical News, Nov 15, 2016

Medscape Gastroenterology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Expert Commentary

Novel Therapies for Cholestasis
William F. Balistreri, MD
Ongoing Trials Put Focus Back on Fatty Liver Disease
William F. Balistreri, MD
'Prehab' for Improved Liver Transplantation Outcomes
William F. Balistreri, MD
Innovations Are Brightening Liver Transplantation Outcomes
William F. Balistreri, MD
Suspect Supplements: Unregulated OTC Meds and Liver Injury
William F. Balistreri, MD

Medscape Board at the Podium

Nancy Reau, MD
Rush University Medical Center, Chicago, Illinois
Presentation: Management of cirrhosis in pregnancy
Date: October 21, 2017

Previous Coverage

Related Resources